PHR

AI Memo

Phreesia

As of 2026-09-24/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Fiscal 2027 outlook tests network-solutions visibility • 2026-12-31

Base target: $11 / p=50% prob

Biggest risk

Revenue growth slowed from 13% in Q1 to 10% in Q2, and management specifically warned of network-solutions forecasting variability. Restructuring execution and AccessOne contribution remain important tests. [#SEC-8K-2026-05-27] [#SEC-8K-2026-09-02]

Invalidation

Break below $7 or thesis failure.

What would change my mind?

Q2 adjusted EBITDA and free cash flow improved while management maintained fiscal 2027 guidance. Sustained client growth, restructuring savings and product commercialization could support a rerating. [#SEC-8K-2026-09-02]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-24

Base target

$11

p=50%

Bull target

$14

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 cash flow and profitability support the thesis
AccessOne and ProviderConnect commercialization
Q2 adjusted EBITDA and free cash flow improved while management maintained fiscal 2027 guidance.

BearKey bullets

Fiscal 2027 guidance assumes approximately $37 million of AccessOne revenue, creating integration and contribution risk.
[#SEC-8K-2026-09-02]
Management cited greater variability in network-solutions revenue forecasting, particularly in the fiscal second half.

WatchKey bullets

Fiscal 2027 outlook tests network-solutions visibility

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $11 (p=50%)

Target spread vs base: +27% / -36%

Scenario probabilities

Bull Target: $14 (p=25%)Base Target: $11 (p=50%)Bear Target: $7 (p=25%)

Commentary

Company-source tone is cautiously constructive, but Q2 was described as in line with expectations and guidance was maintained, not raised. An attributable post-release price reaction, earnings surprise versus consensus, and verified analyst revisions were unavailable. The zero sentiment fields denote unavailable measurements, not neutral readings; social coverage was not supplied.

As of 2026-09-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 cash flow and profitability support the thesis
AccessOne and ProviderConnect commercialization

Scenarios

Bull Target (Scenario probability)

$14 / p=25% prob

Base Target (Scenario probability)

$11 / p=50% prob

Bear Target (Scenario probability)

$7 / p=25% prob

Analysis 2026-09-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Fiscal 2027 outlook tests network-solutions visibility
Phreesia maintained fiscal 2027 revenue guidance of $510 million–$520 million and adjusted EBITDA guidance of $125 million–$135 million. Management flagged greater variability in network-solutions revenue forecasting, especially in the fiscal second half. The next results update could clarify whether that risk is contained; its date is not confirmed here. [#8-K-2026-09-02] [#SEC-8K-2026-09-02]
Prob 55.00% • Move 11.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Q2 cash flow and profitability support the thesis
2026-12-31
Fiscal Q2 revenue rose 10% year over year to $129.5 million, adjusted EBITDA reached $32.9 million, and free cash flow was $13.8 million. Continued cash generation could support the shares, though management characterized the quarter as in line with expectations rather than an upside surprise. [#8-K-2026-09-02] [#SEC-8K-2026-09-02]
Prob 65% • Move 7% • Priced-in 55%

Long-term Catalysts

Months to a year

AccessOne and ProviderConnect commercialization
2027-07-31
Management identified AccessOne and ProviderConnect as potential growth drivers. Fiscal 2027 revenue guidance assumes approximately $37 million from AccessOne, but the available evidence does not quantify ProviderConnect adoption or incremental revenue. Demonstrated contribution beyond current assumptions would strengthen the longer-term case. [#8-K-2026-09-02] [#SEC-8K-2026-09-02]
Prob 45% • Move 20% • Priced-in 25%

Risks

Fiscal 2027 guidance assumes approximately $37 million of AccessOne revenue, creating integration and contribution risk. [#SEC-8K-2026-09-02]
Management cited greater variability in network-solutions revenue forecasting, particularly in the fiscal second half. [#SEC-8K-2026-09-02]
Phreesia reported $61 million outstanding under its credit facility at July 31, 2026. [#SEC-8K-2026-09-02]
The restructuring is expected to cost approximately $10 million; savings and service continuity remain execution risks. [#SEC-8K-2026-09-02]

Peers

Symbol	Summary
ANGO	Similar market capitalization, but its medical-device business is not a direct comparator for Phreesia's healthcare software, network-solutions and payments exposure.
KIDS	Similar market capitalization, but orthopedic-device demand and valuation drivers differ substantially; use only as a loose small-cap healthcare comparator.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-24

Loading AI feed…

Symbol

Summary

ANGO

Similar market capitalization, but its medical-device business is not a direct comparator for Phreesia's healthcare software, network-solutions and payments exposure.

KIDS

Similar market capitalization, but orthopedic-device demand and valuation drivers differ substantially; use only as a loose small-cap healthcare comparator.